FAB-144 is a synthetic cannabinoid (CB) with a tetramethylcyclopropyl group, which reportedly confers selectivity for the peripheral CB2receptor over the central CB1 receptor. FAB-
that acts as a potent agonist for the cannabinoid receptors CB and CB with EC values of 98 nM and 83 nM, respectively. It is a 3-(tetramethylcyclopropylmethanoyl)indole derivative related to compounds such as UR-144, A-796,260 and A-834,735, but it is not specifically listed in the patent or scientific literature alongside these other similar compounds, and appears to have not previously been made by Abbott Laboratories, despite falling within the claims of patent WO 2006/069196. XLR-11 was found to produce rapid, short-lived hypothermic effects in rats at doses of 3 mg/kg and 10 mg/kg, suggesting that it is of comparable potency to APICA and STS-135.